Professor Deborah Mason, Centre Co-Director

Professor Deborah Mason

Professor Deborah Mason, Centre Co-Director

Biomechanics and Bioengineering Research Centre, Cardiff University

ORCiD: 0000-0003-4926-3365

"I’m a molecular cell biologist and lead the pre-clinical research we conduct through the Centre. My main interest is in trying to understand the molecular causes of osteoarthritis to potentially develop new treatments in the future.

Thanks to long-term funding provided by the Centre, we have been able to collect thousands of samples with matched clinical and biomechanics data. Centre resource also enabled us to manage the complex ethics processes required to maintain and store these samples for years. These samples are incredibly valuable; they lay the foundation for all pre-clinical research we do at the Centre."  

Areas of professional expertise

  • Professor, School of Biosciences; Director of Pre-Clinical Research, Cardiff University
  • Research programme uses a range of cell, explant, animal and human models to determine how altered joint biomechanics influences biological signals.
  • Her research has identified new drug targets and biomarkers for osteoarthritis, and developed new in vitro models for drug screening and biomarker selection.

Qualifications and credentials

  • Past President and Chair of Trustees, British Orthopaedic Research Society
  • Translational Theme Lead, Musculoskeletal Research Advisory Group, Arthritis UK
  • ‘Trials in at risk populations’ subtheme lead in NIHR Translational Research Collaboration’s Common Musculoskeletal Conditions Workstream

Research and publications

Jones, R. , Gilbert, S. and Mason, D. 2026. A predictive model for the investigation of osteoarthritic pain [Abstract]. Osteoarthritis and Cartilage 34 (S), pp.S61. (10.1016/j.joca.2026.01.058)

About the Biomechanics and Bioengineering Research Centre

Arthritis UK established the Biomechanics and Bioengineering Centre at Cardiff University in 2009 with £4.5 million of infrastructure funding. It was created to build capacity, address unanswered scientific questions about how our everyday movements affect the health of our joints, seek additional funding, embed patient and public involvement, and build networks.  

How has the centre helped your research?

“Thanks to long-term funding provided by Centre, we have been able to collect thousands of samples with matched clinical and biomechanics data. Centre resource also enabled us to manage the complex ethics processes required to maintain and store these samples for years. These samples are incredibly valuable; they lay the foundation for all pre-clinical research we do at the Centre.  

The Centre also allowed us to build a critical mass of researchers who speak the same ‘language’ across different disciplines. It has created a lasting legacy by funding fellows who are now lecturers, readers and highly successful independent researchers. Through the Centre, we also had access to a scientific advisory board who provided fantastic international expertise. This not only improved our science but opened the field internationally to collaborate with others and share our findings more widely.” 

What has your research discovered?

“The most common cell type in our bones (called osteocytes), which orchestrate bone maintenance and repair, can be modelled to identify molecular drivers of osteoarthritis and test potential drugs. Before our research, osteocytes weren’t considered a key player in osteoarthritis. It was an understudied cell type, and no model existed. We’ve developed an osteocyte model and used our advanced mechanical loading laboratory at the Centre to highlight their true importance. 7,500 genes in an osteocyte respond to a single mechanical stimulus, many of which relate to pain and joint disease.

We have tested a drug in development (called a glutamate receptor antagonist) in comparison with other drugs commonly used for injury, such  as steroids and hyaluronic acid. We found that our drug was far more effective in reducing joint swelling, inflammation and degeneration in mice. This improvement is profound – if this drug was given twice, it could protect joint degeneration by up to 45%. A patent for this glutamate receptor antagonist has been granted, and we are now exploring it’s potential to prevent osteoarthritis in both human and  veterinary medicine.”